MT2 receptor Inhibitors
2 drugsAbout MT2 receptor
The MT2 receptor, also known as melatonin receptor type 2, is a G protein-coupled receptor (GPCR) that regulates the sleep-wake cycle and other circadian rhythms.
As a drug target, the MT2 receptor has led to the development of pharmaceuticals, though there is currently no genetic evidence directly linking it to specific diseases.
Two small molecule drugs, Rozerem (ramelteon) and Ramelteon, are approved to target MT2, both for other therapeutic areas; these are marketed by Takeda and Aurobindo Pharma.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Circadian Rhythm Disorders with only 1 trials.
Top MT2 receptor Drugs
The competitive landscape includes Takeda and Aurobindo Pharma, each with an approved drug.
Low market concentration suggests relatively low barriers to entry for new competitors.
MT2 receptor Drug Modality Landscape
Modalities
Routes of Administration
MT2 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
The lack of diverse modalities represents a whitespace opportunity for novel biologics.
MT2 receptor Clinical Trials 28 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 4 | 3 | 1 | 0 | 75% |
| Phase 3 | 6 | 0 | 5 | 1 | 0% |
| Phase 4 | 15 | 9 | 4 | 2 | 69% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved MT2 receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting MT2 receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
MT2 receptor Drug Approval Timeline (2005 - 2022)
The first drug was approved in 2005, and the most recent in 2013, spanning 9 years.
The limited approval timeline suggests potential saturation or declining interest in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting MT2 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities